Hold ABT: Synthesize tactical discipline with quality compounding in rangebound setup
Hold ABT core position at $109.72 with tactical positioning rather than directional commitment. The technical setup shows converging warnings (RSI 70.8 with bearish divergence, MACD histogram collapsing 97% in 12 sessions, 200 SMA declining at $106.30) against a fundamentally sound franchise (Q2 13% revenue beat, 4.8% comparable growth, raised guidance, $1.35B buyback completing 14M shares, 18x forward P/E, net debt down $3.4B in two years). Deploy 40-45% now to avoid MSFT inert-patience trap; reserve 55-60% behind explicit triggers at $103-106 or $113.45 breakout. Tighten stop to $106.30 daily close (200 SMA invalidation), or to $108 on hot CPI. Diversify with fixed income while 220bp yield gap persists. Upgrade to Buy requires Q3 operating margin recovery to 16-18%, Exact Sciences revenue disclosure, Nutrition pricing commentary, and continued net debt deleveraging. Downside scenario: Q3 margin miss validates $95 re-test.
| Position | Action |
|---|---|
| Current allocation <40% | Deploy 40-45% of intended allocation |
| Price drops to $103-106 confluence zone (10 EMA, 200 SMA, Bollinger mid) | Add 55-60% of reserved capital |
| Breakout above $113.45 on volume >6-7M shares | Add 55-60% of reserved capital |
| Price rallies into $110-113 zone approaching Bollinger resistance | Trim 25-40% of position |
| Daily close below $106.30 (200 SMA invalidation) | Exit or tighten stop |
| August 11 CPI prints hot with yields up 10-15bp | Tighten stop to $108 close |
ABT is a defensive compounder with accelerating growth, management-confirmed buybacks at depressed prices, and a macro tailwind (no cuts, defensive rotation) that makes its 18.1x forward P/E on raised guidance a re-rating opportunity, not an expensive entry.
| Indicator | Value | Signal |
|---|---|---|
| Close | 109.72 | neutral |
| 10 EMA | 106.86 | bullish |
| 50 SMA | 95.81 | bullish |
| 200 SMA | 106.30 | neutral |
| MACD | 3.86 | bullish |
| MACD Signal | 3.75 | bullish |
| MACD Histogram | 0.11 | bearish |
| RSI(14) | 70.80 | bearish |
| Bollinger Middle | 103.90 | bullish |
| Bollinger Upper | 113.45 | neutral |
| Bollinger Lower | 94.35 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
FreeStyle Libre moat is durable and expanding despite GLP-1 narrative
↩ rebuts: “GLP-1 bear thesis that Ozempic/Mounjaro will cannibalize CGM demand”
EV: $120+ · concedes: Pullback to $103-106 would be a reasonable tactical entry point; RSI overbought at 70.8 creates short-term consolidation risk; MACD histogram compression suggests momentum consolidation needed; TTM P/E of 35.6x is technically elevated
ABT at $109.72 is a distribution opportunity, not a buying opportunity — the stock remains -13.7% below its pre-shock close at $124.72, technical momentum is exhausting, and the risk/reward asymmetry (-12% to -25% downside vs. +3% to +9% upside) does not justify initiating or adding longs at current levels.
EV: -12.7% to -25% (downside scenarios) vs. +3.4% to +9.4% (upside scenarios) · concedes: Abbott is a great company with a diversified franchise and real CGM business; Q2 beat-and-raise is real, just less than it appears due to base effects; The $105-107 buy zone would be a reasonable area to consider longs, but only after 200 SMA confirms reversal; 50+ consecutive years of dividend growth is impressive; Buybacks do provide some floor support at depressed valuations
→ vs conservative: The '12-25% downside' cited is absurd for a $190B market cap healthcare giant; a $109 stock with a $106.30 200 SMA stop is only $3.42 risk, not 12-25%
→ vs conservative: Waiting for a pullback to $103-106 before committing capital is unrealistic given $1.35B buyback demand soaking up supply
→ vs conservative: The 'negative risk/reward skew' framing fails because it doesn't account for buyback floor, peer outperformance, or defensive rotation flows
→ vs conservative: The yield argument (2.32% vs 4.5% 10-year) is 'short-sighted'—ABT is a total return equity compounder, not a fixed income substitute
→ vs conservative: Every 'converging technical warning' cited is a lagging indicator; the 200 SMA lags by definition, and price leading it is exactly what you want in a recovery
→ vs neutral: The 'scale in with 1/3 now' strategy is the 'most damaging recommendation' as it institutionalizes timidity and risks missing 80% of the move
→ vs neutral: The neutral approach 'optimizes for the comfort of being right on the entry' rather than 'the outcome of being right on the thesis'
→ vs conservative: The 'bearish divergence' is 'just a normal cooling-off within an uptrend, not a regime change'
→ vs conservative: Waiting for the 200 SMA to confirm is backwards—you'll be paying $115-120 to get in by the time it turns
| ATR(14) | 2.79 | neutral |
| VWMA(20) | 105.90 | bullish |
Support: 106.86 · 106.3 · 103.9 · 95.81 | Resistance: 110.18 · 113.45 · 115 · 120
ABT has recovered +33.8% from the May 11 low of $81.98 to close at $109.72, with price above all key moving averages (10 EMA: 106.86, 50 SMA: 95.81, 200 SMA: 106.30). The 200 SMA remains in a downtrend (was 110.53 on 6/30, now 106.30) and has not yet confirmed the reversal. Short-term momentum is overbought: RSI at 70.80 shows bearish divergence versus the 7/29 peak of 74.4, and the MACD histogram has collapsed from 4.04 on 7/30 to 0.11, indicating fading momentum despite price near highs. Volume confirmation is mixed—VWMA confirms the trend, but today's volume (4.48M) is below average. The recommended action is HOLD with a bias toward trimming into strength rather than adding; do not chase above 110–113 without a pullback to 103–106 or a confirmed breakout above 113.45 on volume. Key support clusters at 106.86 (10 EMA) and 106.30 (200 SMA)—a sustained loss below 106 would re-confirm the bear regime.
Market Cap
$189.86 B
P/E (TTM)
35.62x
Forward P/E
18.10x
PEG Ratio
2.19
P/B
3.71x
Dividend Yield
2.32%
52-Week High
$137.49
52-Week Low
$81.97
Beta
0.581
Revenue (FY2025)
$44,328 million
Revenue (TTM)
$46.58 B
Gross Profit (FY2025)
$25,009 million
Gross Margin
56.4%
Operating Income (FY2025)
$8,053 million
Operating Margin (FY2025)
18.2%
Operating Margin (TTM)
14.7%
Net Income (FY2025)
$6,524 million
Net Income (TTM)
$5.40 B
Profit Margin (TTM)
11.6%
Diluted EPS (FY2025)
$3.72
EPS (TTM)
$3.08
Forward EPS
$6.06
EBITDA (TTM)
$11.68 B
R&D Expense (FY2025)
$2,942 million
SG&A (FY2025)
$12,332 million
Total Assets (FY2025)
$86,713 million
Cash & ST Investments (FY2025)
$8,939 million
Total Debt (FY2025)
$13,860 million
Net Debt (FY2025)
$4,407 million
Stockholders' Equity (FY2025)
$52,130 million
Goodwill (FY2025)
$24.04 B
Goodwill & Intangibles (FY2025)
$29,561 million
Tangible Book Value (FY2025)
$22.57 B
Retained Earnings
$49.78 B
Working Capital (FY2025)
$9,500 million
Current Ratio (FY2025)
1.58x
Debt/Equity
0.27x
ROE
10.6%
ROA
5.3%
Operating Cash Flow (FY2025)
$9,566 million
CapEx (FY2025)
$2,171 million
Free Cash Flow (FY2025)
$7,395 million
Free Cash Flow (TTM)
$7.21 B
Dividends Paid (FY2025)
$4,116 million
Share Repurchases (FY2025)
$893 million
Net Debt Repayments (FY2025)
$1,614 million
End Cash Position (FY2025)
$8,522 million
International Revenue Exposure
35%+
50-Day Average Price
$95.71
200-Day Average Price
$107.68
Strengths
Concerns
Abbott Laboratories is a diversified healthcare bellwether with four business segments generating $44.33 B in FY2025 revenue, with 18.2% operating margins and $7.40 B in free cash flow. The company has aggressively deleveraged (net debt down to $4.41 B from $7.78 B in 2023) while returning $5.0 B to shareholders through dividends and buybacks. The stock trades at a bifurcated valuation: expensive on TTM P/E (35.62x) but reasonable on Forward P/E (18.1x) assuming consensus EPS recovery to $6.06. Key risks include GLP-1 competition to its dominant FreeStyle Libre CGM franchise and $24.04 B in goodwill concentration, while the primary catalyst is FY2026 earnings execution to justify the valuation discount.
Macro: Higher-for-longer rates dominate (86% no cuts in 2026); U.S. recession risk low at 8% (-1.0pp WoW); UK recession 18% (+5.5pp) and Japan 36% (+7.5pp) rising; sticky inflation >4.5% at 20% (-3.0pp WoW), >5% at 12% (-0.5pp WoW); equities faded ahead of Aug 11 CPI print with growth/tech hardest hit; labor market showing cracks supportive of defensive rotation into ABT.